NCT01065558

Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Psyadon Pharma · Industry
• Sex: Male
• Age: 6 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of ecopipam in patients with Lesch-Nyhan Disease (LND). Ecopipam specifically blocks the actions of one chemical in the brain that helps nerves talk to one another; ecopipam does this by stopping the chemical (dopamine) from binding to one of its family of receptors (i.e, the D1 family). LND is a very rare genetic disease. The sponsor is doing this study to find out what side effects ecopipam causes in LND patients, and whether ecopipam may be able to relieve the self-injurious behaviors seen in these patients.

Conditions

• Lesch-Nyhan Disease

Interventions

Type	Name	Description
DRUG	Ecopipam	Tablets, once daily, for two weeks up to 200 mg/day

Timeline

• Start date: 2010-02-01
• Primary completion: 2011-01-01
• Completion: 2011-06-01
• First posted: 2010-02-09
• Last updated: 2013-04-18
• Results posted: 2013-04-18

Locations

2 sites across 1 country: United States